atturos

Timeline of Key Events

 

The Atturos team is now actively seeking seed investment from individuals through a series of tax efficient schemes including the BES and EII initiatives. If you are interested please don’t hesitate to contact Mike.

 

Atturos

OCProDx and other products

Atturos Secures Place in final of 2017 AIB Start-Up Academy

Submission of H2020 SME Instrument Phase 2 application

Jan 2017
Atturos Claim “Most Investible Start-Up” Award at EBAN Event Nov 2016
Aug 2016 Initial results from second evaluation study in multiethnic cohort.

Atturos engages with Business Mentor support from EU.

Atturos team complete H2020 Phase 1 project and initial business plan. We are using the business plan to raise investment in Atturos and are currently engaged in active discussions with several individual and institutional investors.

June 2016 New high sensitivity QQQ installed in Biomarker Evaluation Laboratory.

Atturos holds a series of innovative Brainstorming Sessions chaired by Frost & Sullivan – attendees include patients, clinicians, scientists, entrepreneurs and international business leaders.

Atturos website launched.

May 2016
Atturos Founder redeems UK USS pension fund to release capital to investment to Atturos. April 2016 Academic collaboration agreement with Agilent.
Founding shareholders identified and agree seed investment. Jan 2016
Atturos receives EU H2020 SME Instrument Phase 1. Nov 2015
Atturos applies for EU H2020 SME Instrument Phase 1. Sep 2015
Aug 2015 With St Luke’s Hospital, Pennington and team hold Prostate Cancer Patient research awareness event.
July 2015 Enterprise Ireland Commercialisation Fund awarded with the aim of supporting the technical and clinical evaluation of OCProDx.
June 2015 International patent application WO2015/092046 published.
Jan 2015

Pennington and Team establish dedicated MRM Biomarker Evaluation Laboratory in UCD Conway Institute.

MIAMI FP7 programme awarded: Pennington and Fitzgerald continue discovery and evaluation of protein biomarkers for inflammatory arthritis

Atturos founded with support from Grant Thornton, Dublin Office. Dec 2014 International filing of OCProDx biomarkers patent PCT/EP2014/078914.
Steve presents Atturos elevator pitch at BioConnect Ireland Event and meets Mike Feeney. Oct 2014
Steve Pennington and Brian Flatley attend NovaUCD VentureLaunch programme. Sept 2014
2010 – 2013 With funding from various agencies including the Irish Cancer Society, Pennington and team undertake LC-MS/MS discovery of serum protein biomarkers, MRM development and initial evaluation studies to develop OCProDx biomarker candidate panel.
2006 Armstrong and Pennington begin St Luke’s Institute for Cancer Research (SLICR) funded translational proteomic study as part of ICORG 06-15. Collecting longitudinal patient samples for protein biomarker discovery.
2005 – 2010 Pennington team develop expertise in MRM and label-free LC-MS/MS